文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

黑色素瘤脑转移患者接受立体定向放射外科联合伊匹木单抗与纳武利尤单抗免疫检查点治疗的回顾性单中心毒性分析

Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-01-04

该回顾性单中心研究分析了31例黑色素瘤脑转移患者接受立体定向放射外科(SRS)联合伊匹木单抗与纳武利尤单抗(IPI+NIVO)治疗的毒性特征。结果显示5例(16.1%)患者出现与SRS相关的神经系统3级毒性,全部位于同步治疗组(C组),SRS与IPI+NIVO间隔≤7天与3级毒性显著相关(p=0.048)。作者认为同步应用IPI+NIVO与SRS可能增加副作用,需前瞻性验证。

要点

  • 31例黑色素瘤脑转移患者中,5例(16.1%)出现SRS相关神经系统3级毒性,均位于同步治疗组C组。
  • C组(同步治疗)与3级毒性风险接近显著相关(p=0.058)。
  • 事后分析显示SRS与IPI+NIVO间隔≤7天与3级毒性显著相关(p=0.048)。

核心结论

  • 在该回顾性分析中,SRS与IPI+NIVO在7天窗口内应用与更高的毒性率相关。
  • 作者指出,既往研究关注免疫检查点单药治疗联合SRS并宣称其安全,本研究表明同步应用IPI+NIVO与SRS可能增加副作用。
  • 作者认为需要前瞻性验证以证实这些发现。

研究设计与样本

  • 回顾性单中心毒性分析,检索临床数据库纳入所有接受SRS和IPI+NIVO治疗的黑色素瘤脑转移患者。
  • 患者分为三组:A组在SRS前>14天完成IPI+NIVO(通常最多4周期),B组在SRS后>14天开始IPI+NIVO,C组接受SRS同步IPI+NIVO。
  • 共评估31例患者,A组6例(19.4%),B组7例(22.6%),C组18例(58.1%)。
  • 治疗相关毒性取自临床和神经放射学记录,分析采用Fisher-Yates检验。

主要发现

  • 共5例(16.1%)患者发生与SRS相关的神经系统3级毒性。
  • 全部5例3级毒性患者均位于C组(同步治疗组),C组与3级毒性风险接近显著相关(p=0.058)。
  • 事后分析显示,SRS与IPI+NIVO之间最大间隔7天与3级毒性显著相关(p=0.048)。
  • 各组基线预后标志物均衡。

局限性

  • 本文为回顾性分析。
  • 本文为单中心研究。
  • 作者结论指出需要前瞻性验证以证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE AND OBJECTIVE: Adding stereotactic radiosurgery (SRS) to combined immune checkpoint therapy with ipilimumab and nivolumab (IPI + NIVO) has led to promising results for patients with melanoma brain metastases (MBM). This study retrospectively analyzes the toxicity profile depending on the timing of SRS with regard to IPI + NIVO. MATERIALS AND METHODS: For this study, the clinical database was searched for all patients with MBM who were treated with SRS and IPI + NIVO. The patients were separated into three groups: group A completed IPI + NIVO (usually up to four cycles) >14 days before SRS, in group B IPI + NIVO was initiated>14 days after SRS, and group C received SRS concurrently to IPI + NIVO. Treatment related toxicity was obtained from clinical and neuroradiological records. Analyses were performed using the Fisher-Yates-test. RESULTS: 31 patients were assessed including six (19.4 %), seven (22.6 %) and 18 (58.1 %) patients, in groups A, B and C, respectively. Baseline prognostic markers between groups were balanced. In total, five (16.1 %) patients experienced neurological grade 3 toxicities related to SRS. All of these five patients were in group C, which was near-significantly correlated with a risk for grade 3 toxicities (p = 0.058). Post-hoc analyses showed that a maximum time period of seven days between SRS and IPI + NIVO was significantly correlated with grade 3 toxicity (p = 0.048). CONCLUSION: Application of SRS to IPI + NIVO within a seven-day span was related to higher toxicity rates in this retrospective analysis. After previous studies focused on immune checkpoint monotherapies with SRS and declared it as safe, this study indicates that concomitant application of IPI + NIVO and SRS might increase side effects. Prospective validation is warranted to corroborate these findings.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bodensohn R, Werner S, Reis J, et al. Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis. Clin Transl Radiat Oncol. 2023. PMID: 36655118. doi:10.1016/j.ctro.2022.100573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。